Scientists at UCLA have identified a molecule, PP405, that shows promise in reactivating dormant hair follicles, potentially offering a modern approach to treating hair loss. The findings, released on March 19, 2026, stem from a study where 31% of men with significant hair loss experienced a more than 20% increase in hair density after eight weeks of treatment with a 0.05% PP405 gel, compared to no increase in the placebo group.
Hair loss is a widespread concern affecting both men and women globally. According to data from Medihair, genetics are the primary driver of hair loss, with male pattern baldness accounting for approximately 95% of cases in men. Other contributing factors include diet, stress, lifestyle and underlying medical conditions.
The UCLA study, detailed in a press release from the university, involved applying the PP405 gel or a placebo once daily for four weeks, with follow-up monitoring extending up to 12 weeks. Researchers observed that PP405 not only increased hair density but also stimulated new hair growth in previously barren areas, suggesting a potential regenerative effect. The treatment was also found to be well-tolerated, with no systemic absorption detected in blood plasma.
“None of these products will work for everyone, but our initial human trials have been very encouraging, and larger trials with more participants are on the horizon,” stated a researcher from UCLA, as reported by the university’s press office.
Dr. Pedro Barbosa, a dermatologist specializing in trichology at the Austral University Hospital, noted that PP405 operates through a distinct mechanism compared to existing treatments for androgenetic alopecia. However, he cautioned that the eight-week timeframe of the study is relatively short for observing substantial effects. “Any change in hair will only become visible after 3-6 months; patience is paramount in treatments,” he said.
Barbosa also highlighted the potential advantage of a topical treatment like PP405, minimizing the contraindications and side effects associated with oral medications. He emphasized, however, that even PP405 is unlikely to restore hair growth in cases of advanced baldness where follicles have become permanently scarred.
According to Medihair statistics, Western countries exhibit the highest rates of male pattern baldness: Spain (44.50%), Italy (44.37%), and France (44.25%). Argentina ranks 47th, with 29.35% of men affected. The prevalence of hair loss underscores the emotional impact of the condition and the ongoing search for effective treatments.
While a definitive cure for hair loss remains elusive, the development of PP405 represents a significant step forward. Further research, including larger clinical trials, is planned to confirm the efficacy and long-term effects of the molecule.
Leave a Reply